Mark Neumann
CIK 1756211 · Chief Commercial Officer · last filed 2026-02-05
Mark Neumann is a Chief Commercial Officer who has filed 34 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for MANE, was dated Feb 5, 2026. Across all open-market trades the lifetime net is −$20.6M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
34
-$20.59M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MANE | Chief Commercial Officer | — | $96.07 | — | $0 | 1 | 2026-02-05 |
| Intra-Cellular Therapies, Inc. (ITCI) Delisted | EVP, Chief Commercial Officer | 0 | $131.87 | $0 | -$20.59M | 33 | 2025-04-02 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-05 | MANE | Grant (A) | — | $0 | EDGAR |
| 2025-04-02 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | −52,811 | -$6.97M | EDGAR |
| 2025-03-10 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | +11,790 | -$1.14M | EDGAR |
| 2025-03-04 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | +5,033 | -$475.5K | EDGAR |
| 2025-02-04 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | +6,288 | -$600.6K | EDGAR |
| 2024-08-20 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | — | -$714.7K | EDGAR |
| 2024-03-11 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | −13,132 | -$1.36M | EDGAR |
| 2024-03-08 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Exer (M) | +13,132 | $0 | EDGAR |
| 2024-03-05 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-27 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | — | -$554.5K | EDGAR |